基因突变与骨髓增殖性肿瘤的研究进展  

Progress of gene mutations and myeloproliferative neoplasms

作　　者：高健 陈羽 杨云帆 潘崚[1] Gao Jian;Chen Yu;Yang Yunfan;Pan Ling(Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Internal Medicine,Wuhou Likang Hospital,Chengdu 610041,China)

机构地区：[1]四川大学华西医院血液科,成都610041 [2]成都市武侯利康医院内科,成都610041

出　　处：《白血病．淋巴瘤》2024年第9期565-568,共4页Journal of Leukemia & Lymphoma

摘　　要：BCR-ABL融合基因阴性的慢性骨髓增殖性肿瘤(MPN)是一组起源于单个造血干细胞的肿瘤性疾病,MPN患者的血细胞中存在有多种基因突变,包括"疾病驱动基因突变"和"克隆驱动基因突变"以及"乘客基因突变",这些突变在MPN的发生、发展中发挥重要作用,影响MPN患者的治疗反应和结局,已经纳入MPN国际预后评分系统,对MPN的诊断、治疗方案的选择有重要意义。BCR-ABL1 fusion gene negative chronic myeloproliferative neoplasms(MPN)are a group of malignant disorders that originate from a single hematopoietic stem cells.There are a variety of gene mutations in the blood cells of MPN patients,including"disease driver gene mutation","clone driver gene mutation"and"passenger gene mutation",which play an important role in the development and progression of MPN,and affect the treatment response and outcome of MPN patients.These gene mutations have been included in the MPN international prognostic scoring system.It is of great significance for the diagnosis and treatment of MPN.

关 键 词：骨髓增殖性疾病 突变 基因 预后 

分 类 号：R733.3[医药卫生—肿瘤]